Alexander C Huang
Overview
Explore the profile of Alexander C Huang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
8933
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Guo Y, Wang H, Liu S, Zhang X, Zhu X, Huang L, et al.
Sci Adv
. 2025 Jan;
11(3):eadp9009.
PMID: 39813334
Small extracellular vesicles (sEVs) are nanosized vesicles. Death receptor 5 (DR5) mediates extrinsic apoptosis. We engineer DR5 agonistic single-chain variable fragment (scFv) expression on the surface of sEVs derived from...
2.
Ma K, Mitchell T, Dougher M, Sharon C, Tortorello G, Elder D, et al.
Clin Cancer Res
. 2024 Sep;
30(21):4987-4994.
PMID: 39248505
Purpose: Neoadjuvant anti-PD-1 therapy in melanoma may increase tumor-infiltrating lymphocytes (TIL), and more TIL are associated with better treatment response. A major pathologic response (MPR) in melanoma after neoadjuvant anti-PD-1...
3.
Wang K, Coutifaris P, Brocks D, Wang G, Azar T, Solis S, et al.
Cancer Cell
. 2024 Aug;
42(9):1582-1597.e10.
PMID: 39214097
Combination checkpoint blockade with anti-PD-1 and anti-CTLA-4 antibodies has shown promising efficacy in melanoma. However, the underlying mechanism in humans remains unclear. Here, we perform paired single-cell RNA and T ...
4.
Ngiow S, Manne S, Huang Y, Azar T, Chen Z, Mathew D, et al.
Cell
. 2024 Aug;
187(16):4336-4354.e19.
PMID: 39121847
Exhausted CD8 T (T) cells in chronic viral infection and cancer have sustained co-expression of inhibitory receptors (IRs). T cells can be reinvigorated by blocking IRs, such as PD-1, but...
5.
Mathew D, Marmarelis M, Foley C, Bauml J, Ye D, Ghinnagow R, et al.
Science
. 2024 Jun;
384(6702):eadf1329.
PMID: 38900877
Persistent inflammation driven by cytokines such as type-one interferon (IFN-I) can cause immunosuppression. We show that administration of the Janus kinase 1 (JAK1) inhibitor itacitinib after anti-PD-1 (programmed cell death...
6.
Anderson T, Chang B, Huang A, Xu X, Yoon D, Shang C, et al.
Clin Cancer Res
. 2024 Jan;
30(9):1758-1767.
PMID: 38263597
Purpose: Immunologic response to anti-programmed cell death protein 1 (PD-1) therapy can occur rapidly with T-cell responses detectable in as little as one week. Given that activated immune cells are...
7.
Beltra J, Abdel-Hakeem M, Manne S, Zhang Z, Huang H, Kurachi M, et al.
Immunity
. 2023 Dec;
56(12):2699-2718.e11.
PMID: 38091951
Rewiring exhausted CD8 T (Tex) cells toward functional states remains a therapeutic challenge. Tex cells are epigenetically programmed by the transcription factor Tox. However, epigenetic remodeling occurs as Tex cells...
8.
Painter M, Johnston T, Lundgreen K, Santos J, Qin J, Goel R, et al.
Nat Immunol
. 2023 Sep;
24(10):1711-1724.
PMID: 37735592
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection of vaccinated individuals is increasingly common but rarely results in severe disease, likely due to the enhanced potency and accelerated kinetics of...
9.
Shah P, Huang A, Xu X, Orlowski R, Amaravadi R, Schuchter L, et al.
Cancer Res Commun
. 2023 Jun;
3(5):821-829.
PMID: 37377890
Purpose: Treatments are limited for metastatic melanoma and metastatic triple-negative breast cancer (mTNBC). This pilot phase I trial (NCT03060356) examined the safety and feasibility of intravenous RNA-electroporated chimeric antigen receptor...
10.
Ou L, Liu S, Wang H, Guo Y, Guan L, Shen L, et al.
EBioMedicine
. 2023 May;
92:104614.
PMID: 37229906
Background: Only a minority of melanoma patients experience durable responses to immunotherapies due to inter- and intra-tumoral heterogeneity in melanoma. As a result, there is a pressing need for suitable...